Appeals Court Revives Whistleblower Suit Against Florida Health Care Network

A federal appeals court has thrown out a Florida district judge's ruling that threatened one of the federal government's most powerful anti-fraud tools, holding that private whistleblowers who sue on behalf of the United States are not acting as improperly appointed federal officers. The unanimous three-judge panel of the U.S. Court of Appeals for the Eleventh Circuit revived a Medicare fraud lawsuit against a Florida health care network and preserved the False Claims Act's qui tam mechanism nationwide.

The case, Zafirov v. Florida Medical Associates LLC, was brought by Dr. Clarissa Zafirov, a board-certified family care physician who accused her former employer, doing business as VIPcare, of systematically submitting false Medicare Advantage diagnosis codes in order to inflate monthly risk-adjustment payments.

The stakes extend well beyond one Florida provider. The False Claims Act's qui tam provisions, which date to the Civil War, are the mechanism behind a large share of federal health care fraud recoveries. Florida, with one of the country's largest Medicare populations and a long history of health care fraud enforcement, has more at stake in the statute's survival than almost any other state.

What the district court had held

In 2024, U.S. District Judge Kathryn Kimball Mizelle, a Trump appointee sitting in the Middle District of Florida, ruled that the False Claims Act's qui tam provisions improperly allow private citizens to wield executive branch authority. That made her the first federal judge in the country to strike down the qui tam provisions of a statute that had been in continuous use since 1863.

The reasoning drew on the Appointments Clause of the Constitution, which requires that officers of the United States be appointed by the President, a court, or a department head. A relator, the term for a private party bringing a qui tam suit, is appointed by no one; the person simply files a complaint under seal and the government decides whether to intervene.

The argument had been floating in academic and defense-side litigation for years and had drawn interest from at least one Supreme Court justice in a prior concurrence, which is part of why the district court ruling attracted attention disproportionate to a single trial court decision.

What the Eleventh Circuit decided

The appeals court disagreed, holding unanimously that relators are not officers of the United States within the meaning of the Appointments Clause. The panel's reversal restores Zafirov's case to active litigation and, more consequentially, removes the only appellate-adjacent authority supporting the constitutional challenge.

The distinction the court drew is between exercising government authority and pursuing a statutorily created private right of action on the government's behalf. A relator does not hold a continuing position, does not exercise discretion over enforcement priorities, and operates under a statute that reserves substantial control to the Department of Justice, which may intervene, settle, or move to dismiss.

Because the Eleventh Circuit covers Florida, Georgia and Alabama, the ruling binds district courts throughout those states. Its persuasive weight in other circuits is substantial given that it is the first appellate decision to address the question directly after the district court ruling.

How Medicare Advantage risk adjustment works

Understanding the underlying allegation requires understanding the payment model. Medicare Advantage plans receive a fixed monthly payment per enrollee rather than payment per service. That monthly amount is adjusted upward for enrollees with documented chronic conditions, on the theory that sicker patients cost more to care for.

The mechanism creates an obvious incentive. A diagnosis code added to a patient's record increases the monthly payment for that patient whether or not any additional care is provided. Federal enforcement in this area has focused on providers and plans alleged to have added codes for conditions patients did not have or that were not supported by clinical documentation.

Zafirov's allegation is that VIPcare systematically submitted false diagnosis codes to inflate those risk-adjustment payments. Those allegations remain allegations; the appeals court decided a constitutional question about who may bring the suit, not whether the conduct occurred.

Why this matters in Florida specifically

Florida has the second-largest Medicare population in the country and one of the highest Medicare Advantage penetration rates. A large share of Florida seniors receive care through Medicare Advantage plans, which means the risk-adjustment payment model governs a substantial portion of health care delivery in the state.

Florida also has a long enforcement history. The Southern District of Florida in particular has been a center of federal health care fraud prosecution for decades, and the Health Care Fraud Prevention and Enforcement Action Team has repeatedly identified South Florida as a focus area.

Qui tam suits are central to that enforcement because fraud in this area is difficult to detect from claims data alone. The people who know that diagnosis codes are being added without clinical basis are the clinicians and coders inside the organization, and the statute's financial incentive, which allows relators to receive a share of any recovery, is what makes them willing to come forward at the cost of their careers.

What would have happened if the ruling stood

Had the district court decision survived, the practical consequence would have been the elimination of private whistleblower suits under the False Claims Act, at least within the circuit and potentially nationwide had other courts followed.

The Department of Justice would have retained authority to bring FCA cases directly, but the volume would have collapsed. The government does not have the investigative capacity to identify fraud that whistleblowers surface, and a substantial majority of FCA recoveries in recent decades have originated in qui tam filings.

Pending cases would have faced dismissal, including cases in which the government had intervened after years of investigation. The disruption to ongoing federal fraud enforcement would have been significant and immediate.

What happens to this case now

Zafirov's suit returns to the district court for further proceedings on the merits, where the question becomes whether the alleged conduct occurred and whether it violated the statute. That is an entirely different inquiry from the constitutional question the appeals court resolved.

Defendants in the case may seek further review, either by asking the full Eleventh Circuit to rehear the case en banc or by petitioning the Supreme Court. Given the constitutional dimension and the prior expression of interest from the high court, a certiorari petition would not be a long shot to be considered, though the odds of any individual petition being granted remain low.

Providers across Florida operating under Medicare Advantage risk-adjustment arrangements will be reviewing coding compliance programs regardless of the litigation's ultimate path, because the ruling restores the enforcement exposure that the district court decision had briefly appeared to remove.

How qui tam cases actually work

The procedure is unusual enough that it is worth walking through. A relator files a complaint under seal in federal court, meaning the defendant is not served and does not learn of the case. The complaint goes to the Department of Justice along with a written disclosure of substantially all material evidence the relator possesses.

The government then investigates, often for years. Seals are routinely extended, and it is not unusual for a health care fraud complaint to remain under seal for three or four years while investigators issue civil investigative demands, review claims data and interview witnesses. During that period the relator typically continues working, or has already left, and cannot discuss the case with anyone.

At the end of the investigation the government decides whether to intervene. If it does, the Justice Department takes over primary responsibility and the relator receives a smaller share of any recovery, generally 15 to 25 percent. If the government declines, the relator may proceed alone, and the share rises to between 25 and 30 percent. Declined cases are substantially harder to win, and most are dropped.

That structure is the government control the Eleventh Circuit pointed to. The Justice Department may intervene at any time for good cause, may settle over the relator's objection, and may move to dismiss the case entirely. A relator operating under those constraints looks considerably less like an officer wielding independent executive power than the district court's framing suggested.

What the ruling does not decide

It is worth separating the constitutional holding from the underlying allegations. The Eleventh Circuit decided who may bring a False Claims Act case. It did not decide whether VIPcare or Florida Medical Associates did anything wrong.

Those allegations return to the district court where they will be litigated on the merits, with the ordinary burdens of proof and the ordinary defenses available. Risk-adjustment coding disputes are technically complex, and providers frequently argue that codes reflected genuine clinical findings documented by treating physicians, that coding guidance is ambiguous, and that the government's retrospective audits apply standards not in effect at the time.

Falsity under the False Claims Act also requires more than disagreement about clinical judgment. Courts have grappled extensively with whether a physician's opinion can be false, and the answer has generally been that an opinion not honestly held or lacking any reasonable basis can support liability while a good-faith clinical judgment cannot.

None of that is resolved by the appellate ruling. What the ruling resolves is that the case gets to be litigated at all, which for several months it appeared it would not.

What's next

Watch for an en banc petition or a Supreme Court filing over the coming months, which would extend the constitutional question's life. Absent that, the Eleventh Circuit's decision settles the issue in Florida.

Watch also for renewed qui tam filing activity. Relators' counsel had been cautious about bringing new cases in the Middle District of Florida while the constitutional question was live, and that caution should now ease.

For Florida Medicare beneficiaries, the case is a reminder of how the payment system behind their coverage works. Risk-adjustment payments are invisible to patients, but they shape which conditions appear in medical records and how aggressively providers document them, and enforcement of the rules governing that documentation is what the False Claims Act is for.